Header Logo

Connection

Matthew Wanat to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Matthew Wanat has written about Cost-Benefit Analysis.
Matthew Wanat
Connection Strength
0.235
Cost-Benefit Analysis
  1. Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
    View in: PubMed
    Score: 0.235
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.